GlyCanDrug will provide an international, intersectoral and interdisciplinary educational program. According with the EU Principles for Innovative Doctoral Training, it will allow the DCs to obtain skills and knowledge necessary for a career development both in academia and/or private sector.

Training activities are organized in four levels and involve:

1. Skills/knowledges acquired via the Individual Research Project. DCs will acquire multifaceted practical and technical skills that gravitate around the scientific core programme i.e glycoscience (glycochemistry & glycobiology), organic and medicinal chemistry, analytical and computational chemistry, structural and cancer cell biology, biotechnology and nanoscience.

2. Local PhD schools training activities. DCs will attend courses at the home institution for both research and soft skills training.

      • University of Florence, Florence, ITALY (link)
      • i3S-Instituto De Investigação E Inovação Em Saúde Da Universidade Do Porto, Porto, PORTUGAL (link)
      • Universidad De Zaragoza, Zaragoza, SPAIN (link)
      • Danmarks Tekniske Universitet, Copenhagen, DENMARK (link)
      • Univerza V Ljubljani, Ljubiana, SLOVENIA (link)
      • Agencia Estatal Consejo Superior De Investigaciones Cientificas, Siviglia, SPAIN (link)
      • Centre National de la Recherche Scientifique, Lille, FRANCE (link)
      • Glycodisplay Aps, Copenhagen, DENMARK (link)

3. Network-wide training activities. GlyCanDrug consortium will organize well-structured, interdisciplinary and international training courses (link) with the commitment of prestigious academic European/US organizations and SMEs. These activities will include training (i) by research; (ii) in transferable skills related to research and innovation; (iii) in transferable skills related to management; and (iv) IPR/valorisation and dissemination of science. Round tables are planned, where DCs will have the opportunity to discuss with the industrial partners and one expert on translational science about business, entrepreneurship, start-up, bench-to-bedside translation of scientific results, regulatory & safety issues.

4. Secondments. Each DC will have one secondment in a SME (beneficiary or associate partner) to guarantee the industrial relevance of each research project and one secondment in another beneficiary academic partner with interdisciplinary expertise.